The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of Research Institutes publicly funded by the federal and the state governments of Germany. Additionally, the Max Planck Society and its Institutes receive third party funding from public and private contributions and from the European Union. The world leading organization is named in honor of its former president, theoretical physicist Max Planck. The 86 Institutes and Research Facilities of the Max Planck Society (as of 2020) conduct basic research in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 24,000 permanent employees, including 15,000 scientists, and around 5,000 non-tenured scientists and guests. As of December 31, 2018, the proportion of female employees was 44.4 percent. The Max Planck Society (with its 86 Max Planck Institutes) has a world-leading reputation as a science and technology research organization, with more than 33 Nobel Prizes awarded to its scientists, and is widely regarded as one of the foremost basic research organizations in the world.

Genomic Health, Inc. (NASDAQ: GHDX) is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of the unique characteristics of the Shuttle.

Part of Pfizer Inc., Apollon, Inc. is an American company located in Malvern, PA. The firm develops non viral DNA-based vaccines. It was founded by Vincent R. Zurawski. On May 11, 1998 Wyeth Corp., now a subsidiary of Pfizer Inc. acquired Apollon, Inc.

Beijing Nuosai Genome Research Center Co., Ltd., established on 1998-09-24, The scope of business includes the development of genetic engineering and bioengineering technologies and products,to develop,Sales;technology development,technology transfer,technical consulting,Technical Services,Technical testing;Biological and genetic analysis instruments,information equipment,Development of Medical Devices,to develop,Sales;Information Consulting;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;software development;Conference Services;selling computers,Software and Auxiliary Equipment;health management,Health Advisory(Except for medical treatment activities subject to approval);Sales of medical devicesIkind,medical instrumentsIIkind;production of medical devicesIkind;Natural science research and experimental development;Medical Research and Experimental Development;Sales No.IIIclass of medical devices;Production No.IIkind,No.IIIclass of medical devices;medical examination medical service.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Production No.IIkind,No.IIIclass of medical devices,Sales No.IIIclass of medical devices,Medical testing and medical services and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Part of Bayer AG, BlueRock Therapeutics LP is an American company located in Cambridge, MA. The firm operates as an engineered cell therapy company which develops regenerative medicines for intractable diseases.

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

Message Pharmaceuticals, Inc. develops pharmaceutical drugs. It operates as research development company involved in RNA research and exploring other types of RNAs to look for RNA-binding proteins, especially to combat RNA viruses and to treat all major disease categories. Message Pharmaceuticals was founded in 2002 and is located in Malvern, PA

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Nanjing Xinyihua Group Co., Ltd., established on 1999-12-09, Business scope includes genetic diagnosis technology,Various Gene Chips,Development of detection instrument system,Production;Hospital Consulting and Management;computer software development;aquaculture;Flowers and Nurseries,Construction and operation of environmental pollution control facilities;Sell ​​self-produced products;gene therapy drugs,Medical Diagnostic Reagents,Preparation of medical device projects(Not allowed to engage in business during the preparation period,Specific approval of business scope after obtaining relevant licenses).

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Ark Therapeutics Ltd. engaged in manufacturing of pharmaceutical products. The company was founded on April 30, 2018 and is headquartered in London, the United Kingdom.